Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treatment with approved antihistamine doses. The data were published today in the New England Journal of Medicine and will be presented tomorrow at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Antonio, Texas. Omalizumab is not indicated for CIU.

The primary endpoint was measured using a 21-point scale known as a weekly Itch Severity Score (ISS). The study met its primary endpoint, showing that omalizumab given at doses of 150 mg and 300 mg every four weeks led to significant improvement from baseline at Week 12 in the mean weekly ISS from baseline (approximately 14 in all treatment groups) by 8.1 (p=0.001) and 9.8 (p<0.001), respectively, compared to a 5.1 improvement in patients on placebo. The omalizumab 75 mg dose group did not demonstrate statistical significance compared to placebo for the primary endpoint. All eight pre-specified secondary endpoints in the ASTERIA II trial were met for the 150 mg and 300 mg doses, except for the 150 mg dose that did not show a significant difference from placebo in the proportion of angioedema-free days from Week 4 to Week 12 of therapy.

CIU is a distressing skin condition characterized by red, swollen, itchy and sometimes painful hives on the skin, spontaneously presenting and reoccurring for more than six weeks. At any given time, the prevalence of CIU is 0.5% to 1% worldwide. While antihistamines are used first to treat CIU, more than 50% of patients are unable to achieve symptom relief with approved doses.

"These results indicate that omal
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year 2015 results on Thursday, January 22, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:12/19/2014)... Dec. 18, 2014 Since last month,s FBI ... now known as the leading online black market for ... growth in its offering of drugs and other illegal ... the takedowns did succeed in lowering the numbers of ... of the markets in August. But some new sites ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 /PRNewswire/ ... and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced ... insulin, known as BioChaperone Lispro, for treatment in people ... relies on Adocia,s proprietary BioChaperone® technology and is currently ... will develop BioChaperone Lispro with the goal of optimizing ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... April 25, 2007 /PRNewswire-USNewswire/ -- At least,one-third of ... in childhood or adolescence. However, in children, it ... of other,disorders, notes the May 2007 issue of ... children, usually do not show the,adult cycle of ...
... GmbH (Langenfeld,Germany), a specialty pharmaceutics company announces ... for their proprietary,Sufentanil transdermal patch. , “Today, ... of the second clinical trial for our ... to complete this study in,the first half ...
Cached Medicine Technology:Bipolar Disorder in Children Difficult to Diagnose, Reports the,Harvard Mental Health Letter 2Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2
(Date:12/19/2014)... Wilmington, VT (PRWEB) December 19, 2014 ... full-service private ski club in Southern Vermont’s Deerfield Valley, ... trail names inspired by classic rock songs. , ... the weekend with a private concert followed by a ... said, “The new trail names include: “I’m Alright” the ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. ... might slightly reduce your risk of developing a form ... (Advil, Motrin) and naproxen (Aleve) appear to reduce the ... the researchers concluded after reviewing nine prior studies. Squamous ... These painkillers "have potential as part ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Dr. Myo Nwe ... Weight Loss Diet of the Future” and co-founder of the ... her book, Dr. Nwe takes a broad look at the ... hold up under scientific scrutiny. On film and in television ... emphasized mostly toward the social aspects and played for basic ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 In its ... and its Argus Claim Review division have recently ... the most common ways savings are achieved on behalf ... attributes millions of dollars in savings to Argus each ... 2013. , As explained by Tom Doney, Cypress president ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... one worrisome phenomenon is when an illness that originated in ... as zoonosis -- is not uncommon and keeps researchers on ... disease might make inroads into the human population. A ... the culprits in this case were guinea pigs. More specifically, ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... Focussing on healthcare needs of the country, Prime Minister ... National Development Council (NDC) to discuss disease control and ... to review the implementation of the National Rural Health ... attention to healthcare issues and ensure efficient functioning of ...
... to a new study at Cincinnati Children's Hospital Medical ... determine whether children with chronic diseases like Crohn's, juvenile ... cancer treatment -- are at increased risk for bone ... ,There is a huge demand for this ...
... in the Department of Obstetrics, Gynecology & Reproductive Sciences ... in understanding Fragile X mental retardation protein ... Fragile X syndrome(FXS). ,Fragile X syndrome, the ... by a mutation in the FMR1 gene on the ...
... of Florida researchers report the talcum powder stunts growth ... blood .The talc stimulates healthy cells to produce ... metastatic lung cancer. The UF researchers say talc is ... considered incurable. ,Talcum powder has been used ...
... Ministers of polio affected States organized today to review ... Health & Family Welfare, Dr. Anbumani Ramadoss said ... of immunity in all polio-affected States by vaccinating all ... immunization and Supplementary Immunization Activities (SIAs), so that the ...
... University Medical Center say they are moving closer to ... has become resistant to drug treatment in the ... construct, and then express in yeast, a protozoan gene ... they laboriously constructed over a two-year period is believed ...
Cached Medicine News:Health News:A Pratical Tool to Detect Bone Mass Deficiencies in Children With Chronic Diseases 2Health News:A Pratical Tool to Detect Bone Mass Deficiencies in Children With Chronic Diseases 3Health News:A Pratical Tool to Detect Bone Mass Deficiencies in Children With Chronic Diseases 4Health News:New Findings in Fragile X Mental Retardation Protein 2Health News:Talcum Powder Curbs Lung Tumor Risk 2Health News:Talcum Powder Curbs Lung Tumor Risk 3Health News:Every Child Needs to Be Vaccinated to Lead India into a Polio Free Future - Ramadoss 2Health News:New Insights into Antimalarial Drug Resistance 2Health News:New Insights into Antimalarial Drug Resistance 3Health News:New Insights into Antimalarial Drug Resistance 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: